The highly touted gene-editing technology CRISPR is facing one of its first real-world tests. As many as 12 patients who live with the blood disorders sickle cell anemia or beta-thalassemia have started enrolling in a Europe-based clinical trial that may serve as an early indicator of whether gene editing will live up to the hype.
You thought the Shark Tank was tough…
Wait until you enter the the BioHealth Capital Region Crab Trap!
Submit your application for the opportunity to present your innovation and be named the region’s early stage biohealth company with the most commercial potential at the 2019 BioHealth Regional Forum, $10,000, and MORE!
Application Deadline: March 1, 2019
Finalists will be announced: March 21st, 2019
Finalist Presentations BioHealth Capital Region Forum event: April 9th, 2019
Washington, D.C. has been crowned as the city that’s leading the way in talent competitiveness, thanks to its ability to attract and nurture entrepreneurs, whilst meeting the needs of being a strongly-connected, “global” city.
The partners at SR One, a storied corporate biotech VC with investments across a wide range of drug developers on both sides of the Atlantic, are engaged in talks to split away from the pharma giant GlaxoSmithKline, according to sources familiar with a move that’s been in the works since at least late last year.
gel-e Inc., announces the issuance of United States Patent Number 10,179,145 by the U.S. Patent and Trademark Office, which broadly claims and discloses uses of the Company’s core technology.
HOLD THE DATE – February 28, 2019 8 am. – 3:00 p.m.
Meet 1:1 with SBIR program managers. Learn more about their funding programs (SBIR and more!)
8-8:30 Networking and Registration
8:30 – 12:00 p.m. – Program Overviews
12:00 p.m. – 1:00 p.m. – Networking Lunch
1:00 p.m. – 3:00 p.m – 1:1 Meetings with Program Managers*
Agencies represented include:
NSF, NIH NIA, NIH NCI, NIH NHLBI, NIH NIDA, US Army (invited)
*The program overview will be available by videoconference.
**You do not have to participate in 1:1 meetings. However, to do so, you must attend the overview session in person.
PRE-REGISTRATION IS REQUIRED: RSVP by noon 2/26: BHI@BioHealthInnovation.org
After weeks of speculation that biopharma deal making would cool off, 2019 got off to a flying start as far as mergers-and-acquisitions (M&A) is concerned, thanks to two blockbuster transactions: Bristol-Myers Squibb’s planned $74 billion acquisition of Celgene, followed four days later by Eli Lilly’s planned $8 billion purchase of Loxo Oncology—a deal that quickly became the buzz of the J.P. Morgan 37th Healthcare Conference, held earlier this month in San Francisco.
Our National Cancer Institute-University of Maryland (NCI-UMD) Partnership for Integrative Cancer Research reflects the broad interests of our participating NCI and UMD researchers. We are delighted to invite you to our annual NCI-UMD Partnership for Integrative Cancer Research Symposium on Friday, February 8th from 10am-4pm which will take place in Bethesda, Maryland in the John Edward Porter Neuroscience Research Center at the National Institutes of Health, Bldg 35A, Room 620/630. Please register and plan to participate in our October symposium. The final agenda will be announced shortly.
The past decade has seen intensified research collaboration between pharmaceutical companies and academic institutions. Although such partnerships are recognized as a source of innovation and a key pillar to advance science in drug discovery, they are replete with challenges. Despite much anecdotal evidence and debate, fact-based evidence on the nature of these challenges and how to manage them is scarce.
Deloitte has surpassed its peers to become the world’s most valuable professional services brand, according to the 2019 Global 500 report issued by Brand Finance on 22 January 2019. Deloitte’s strong performance was due to higher scores in Brand Finance’s metrics of familiarity, consideration, satisfaction, preference, recommendation and revenue.
